Fertility treatment is one of the most jurisdiction-dependent areas of medical tourism. The legal status of donor gametes, surrogacy, embryo freezing, genetic testing, same-sex and single-parent treatment, and ownership of genetic material varies significantly between countries — and what is legal in the destination country may not be recognised in your home country, creating complications when you return. This guide outlines the main legal and ethical issues to work through before booking fertility care abroad.
Why fertility law diverges so much
Fertility regulation touches on unsettled questions about parenthood, reproductive autonomy, the status of embryos, and the rights of donor-conceived people. Different societies have resolved these questions differently — often after long political debates — and the legal frameworks reflect those different resolutions. This means that treatments available and lawful in one jurisdiction may be unavailable or unlawful in another, and that a treatment begun in one jurisdiction may face recognition issues in another.
A concrete example: egg donation is anonymous in some countries (Spain), non-anonymous in others (UK, where donor-conceived people can access donor identity at 18), and the legal framework changes which donors are available, how much information is recorded, and what rights the resulting child has. A UK patient who uses an anonymous donor in Spain and returns to the UK has a child whose legal position under UK law is different from a child conceived with a UK-identifiable donor.
Donor anonymity
The major distinction is between jurisdictions where donors are identifiable (UK, most of Northern Europe for children conceived after 2005, Sweden, New Zealand, several US states by contract) and jurisdictions where donors are anonymous (Spain, Greece, Portugal, the Czech Republic, and several others).
**Clinical implications:** in identifiable-donor jurisdictions, donor-conceived people can typically access non-identifying donor medical information in childhood and identifying information at age 18 (or equivalent). This allows the donor-conceived person to understand their genetic heritage and to initiate contact if they wish.
**Legal implications for cross-border treatment:** if you use an anonymous donor abroad and return to a jurisdiction that requires donor identifiability, the child will grow up in a jurisdiction where peers have access to donor information but they do not. Some jurisdictions have specific law about recognising foreign donor conception; most do not. The practical consequence is usually limited for the parents but can be significant for the child later.
**Ethical considerations:** consider what the child will want as an adult, not what is convenient for you as a prospective parent. Donor-conceived-person advocacy organisations have made a clear case for donor identifiability as an issue of the child's right to know their genetic heritage. Weighing that against the availability or waiting-list advantages of an anonymous-donor jurisdiction is a decision that deserves considered thought.
Surrogacy
Surrogacy is the most jurisdictionally variable fertility-related service. At one end, some countries explicitly allow commercial surrogacy with recognised legal frameworks (Ukraine historically, Georgia, some US states). At the other end, some countries prohibit surrogacy entirely (France, Germany). In between, many countries permit altruistic surrogacy (UK, Canada, Greece for residents) but prohibit commercial surrogacy.
If you are considering cross-border surrogacy, the legal complexity is substantial. Key questions:
- Is the arrangement legally enforceable in the destination country? - Who will be recognised as the legal parents — the intending parents, the surrogate, or both/neither — under the destination country's law? - Will your home country recognise the parentage established in the destination country? - What is the process to bring the child home (passport, visa, parentage documentation)? - What are the rights of the surrogate under the destination country's law, and are they protected?
Several high-profile cases over the past decade have illustrated what happens when the legal picture is not clarified in advance — children stranded abroad for months while parentage and citizenship are resolved, contested parentage in courts of two jurisdictions, and surrogates exposed to exploitation in jurisdictions without clear protections.
In the UK, surrogacy arrangements are not legally enforceable; the birth mother (the surrogate) is the child's legal mother at birth; parental rights have to be transferred to the intending parents through a Parental Order application after the birth. This is true regardless of where the surrogacy took place. UK intending parents using surrogates abroad need to plan for this UK-law step in addition to any destination-country procedures.
Embryo storage and ownership
If you create embryos in one country and subsequently need to move them to another, the legal framework around embryo storage, consent, disposal, and transfer becomes important. Embryo shipping is technically straightforward but involves specific carriers, documentation, and regulatory clearance in both the origin and destination countries.
Consent for storage is typically time-limited in most jurisdictions and requires periodic renewal. In the UK, HFEA rules allow storage up to 55 years with periodic renewal of consent from both gamete providers. If one gamete provider dies or becomes incapacitated, the remaining provider's consent is insufficient on its own — the embryos cannot be used without the deceased provider's prior written consent specifying that use. Similar rules apply in other regulated jurisdictions.
Read the consent forms carefully. Understand what happens to embryos in the event of relationship breakdown, death, or loss of capacity. Many of the most contentious legal cases in fertility law have arisen from ambiguity at this stage.
Pre-implantation genetic testing
The legal status of pre-implantation genetic testing (PGT-A for aneuploidy, PGT-M for single-gene disorders, PGT-SR for structural rearrangements, and HLA matching for sibling donor cases) varies across jurisdictions. Some countries permit all PGT variants; some permit only PGT-M for serious disease; a few prohibit most forms of PGT.
Sex selection for non-medical reasons is particularly variable — permitted in some destinations, prohibited in most European jurisdictions, and restricted to medical indications in the UK. If you are travelling specifically for a PGT indication, confirm the destination country permits what you need and that your home country has no specific rules against it.
Payments and remuneration
Payment to donors varies significantly. Some jurisdictions prohibit donor payment entirely; some permit expenses only; some permit compensation (capped in most EU countries). The relevance to intending parents is partly ethical — whether you are comfortable with the remuneration framework of the destination — and partly practical, since payment affects donor availability and demographic profile.
For surrogacy, payment to the surrogate is even more variable: several jurisdictions expressly prohibit commercial surrogacy, and structuring payments around that prohibition is a legal grey area in many countries. Professional advice from a lawyer familiar with surrogacy in both jurisdictions is essential before entering any cross-border arrangement.
Same-sex couples and single parents
Access to fertility treatment for same-sex couples and single parents varies by jurisdiction and by clinic. Several well-known fertility-tourism destinations restrict treatment to married heterosexual couples; others are open. If you are in a category that is restricted in some jurisdictions, filter destinations accordingly — do not assume that a clinic's willingness to accept international patients means it is open to all categories of patient.
Success rate claims
Fertility clinics have particularly high incentive to present success rates favourably. Before choosing a clinic abroad, look for independently reported outcome data — published in national registries (SEF in Spain, HFEA in the UK, SART in the US) or in peer-reviewed journals. Clinic-reported marketing data is often selected for the most favourable cohort and is not directly comparable between clinics.
The Spanish SEF registry, the HFEA published clinic data, and the US SART clinic outcome database are three useful reference points. Where a clinic's published self-reported success rates are substantially higher than national averages for comparable patient demographics, the most likely explanation is selection of the reported cohort rather than unusual clinical results.
Legal advice is not optional
For fertility treatment abroad, the legal complexity is high enough that generic guidance is insufficient. Consult a family lawyer with specific cross-border fertility experience before committing to a surrogacy arrangement, using donor gametes in a jurisdiction with different rules from yours, or shipping genetic material across borders. The cost of legal advice is small compared to the cost of an unresolved legal position after treatment has started.